Inclusion Criteria:

          1. Part A: Patients with histologically or cytologically confirmed malignant advanced
             solid tumours refractory to standard therapy or for which no suitable effective
             standard therapy exists, including, but not limited to patients with: BRCA1/2 mutant
             cancers, TNBC, CRPC and HGSOC, and those with somatic mutations or other aberrations
             known to result in a hyperactivated PI3K-AKT pathway.

             Part B: (1) BRCA1/2 mutation cohort: Patients with advanced germline BRCA1/2 mutant
             solid tumours; (2) Sporadic cancers cohort: This cohort will include advanced sporadic
             cancers that are not known to harbour germline BRCA1/2 mutations, but which may
             harbour homologous recombination (HR) defects, e.g. advanced TNBC, CRPC and HGSOC, and
             those with somatic mutations or other aberrations known to result in a hyperactivated
             PI3K-AKT pathway.

          2. Life expectancy of at least 12 weeks

          3. WHO performance status of 0-1 with no significant deterioration over the previous 2
             weeks

          4. Evaluable or measurable disease as assessed by RECIST 1.1

          5. Haematological and biochemical indices within the ranges shown below. These
             measurements must be performed within one week.

               -  Hb ≥ 10.0 g/dL

               -  Absolute neutrophil count ≥ 1.5 x 109/L

               -  Platelet count ≥ 100 x 109/L

               -  Serum bilirubin ≤ 1.5 x upper limit of normal except for patient with documented
                  Gilburt's disease

               -  ALT or AST ≤ 2.5 x (ULN) unless raised due to tumour in which case up to 5 times
                  ULN is permissible

        If creatinine > 1.5 times ULN then: Either:

          -  Creatinine Clearance ≥ 50 mL/min (uncorrected value)

          -  Isotope clearance measurement ≥ 50 mL/min (corrected) 6.18 years or over 7. Signed and
             dated informed consent and be capable of co-operating with treatment and follow-up

        Exclusion Criteria:

          1. Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or
             chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C)
             and 4 weeks for investigational medicinal products before treatment, except for
             hormonal therapy with luteinizing hormone-releasing hormone analogues for medical
             castration in patients with CRPC, which are permitted.

          2. Ongoing toxic manifestations of previous treatments. Exceptions to this are Grade 1
             toxicities, which in the opinion of the Investigator should not exclude the patient.

          3. Ability to become pregnant (or already pregnant or lactating). However, those female
             patients who have a negative serum or urine pregnancy test before enrolment and agree
             to use two highly effective forms of contraception (oral, injected or implanted
             hormonal contraception and condom, have an intra-uterine device and condom, diaphragm
             with spermicidal gel and condom) for four weeks before entering the trial, during the
             trial and for six months afterwards are considered eligible.

          4. Male patients with partners of child-bearing potential (unless they agree to take
             measures not to father children by using one form of highly effective contraception
             [condom plus spermicide] during the trial and for six months afterwards). Men with
             pregnant or lactating partners should be advised to use barrier method contraception
             (for example, condom plus spermicidal gel) to prevent exposure to the foetus or
             neonate.

          5. Major surgery (excluding minor procedures, e.g. placement of vascular access) within 4
             weeks of the first dose of study treatment.

          6. At high medical risk because of severe or uncontrolled systemic disease including
             active bleeding diathesis or active infection including hepatitis B, hepatitis C and
             human immunodeficiency virus. Screening for chronic conditions is not required.

          7. Clinically significant abnormalities of glucose metabolism as defined by any of the
             following:

               -  Diagnosis of diabetes mellitus type I or II (irrespective of management).

               -  HbA1C ≥ 8.0% at screening (64 mmol/mol) (conversion equation for HbA1C
                  [IFCC-HbA1C (mmol/mol)] = [DCCT-HbA1C (%) - 2.15] x 10.929)

               -  Fasting Plasma Glucose ≥ 8.9mmol/L at screening. Fasting is defined as no caloric
                  intake for at least 8 hours.

          8. Proteinuria 3+ on dipstick analysis or >500mg/24 hours.

          9. Previous treatment with a PARP inhibitor or PI3K/AKT inhibitor (Part B: sporadic
             cancers arm of dose expansion cohort only).

         10. Treatment with potent inhibitors or inducers or substrates of CYP3A4 or substrates of
             CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John's
             Wort).

         11. Spinal cord compression or brain metastases unless asymptomatic, treated and stable
             and not requiring steroids for at least 4 weeks prior to start of study treatment

         12. Any of the following cardiac criteria:

               -  Mean resting corrected QT interval (QTc) > 470 msec obtained from 3 consecutive
                  electrocardiograms

               -  Any clinically significant abnormalities in rhythm, conduction or morphology of
                  resting ECG

               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events, such as heart failure, hypokalaemia, congenital long QT syndrome, family
                  history of long QT syndrome or unexplained sudden death under 40 years of age or
                  any concomitant medication known to prolong the QT interval

               -  Experience of any of the following procedures or conditions in the preceding 6
                  months: coronary artery bypass graft, angioplasty, vascular stent, myocardial
                  infarction, angina pectoris, congestive heart failure New York Heart Association
                  [NYHA0 Grade 2

               -  Uncontrolled hypotension - Systolic BP <90mmHg and/or diastolic BP <50mmHg

               -  LVEF below institutional lower limit of normal.

         13. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
             swallow the formulated product or previous significant bowel resection that would
             preclude adequate absorption of olaparib and AZD5363.

         14. History of hypersensitivity to active or inactive excipients of AZD5363 or olaparib or
             drugs with a similar chemical structure or class to AZD5363 and olaparib.

         15. Is a participant or plans to participate in another interventional clinical trial,
             whilst taking part in this Phase I study. Participation in an observational trial
             would be acceptable.

         16. Any other condition which in the Investigator's opinion would not make the patient a
             good candidate for the clinical trial.

         17. Patients with myelodysplastic syndrome or acute myeloid leukaemia